Liver function in transgender persons:Challenges in the COVID-19 era  

作　　者：Charalampos Milionis Ioannis Ilias Eftychia Koukkou 

机构地区：[1]Department of Endocrinology,Diabetes and Metabolism,Elena Venizelou Hospital,Athens GR-11521,Greece

出　　处：《World Journal of Clinical Cases》2023年第2期299-307,共9页世界临床病例杂志

摘　　要：Transgender persons constitute a non-negligible percentage of the general population.Physical gender-transitioning in trans persons is mainly achieved with hormonal cross-sex therapy and sex reassignment surgeries that aim to align bodily appearance with gender identity.Hormonal treatment acts via suppressing the secretion of the endogenous sex hormones and replacing them with the hormones of the desired sex.The administration of testosterone is the typical masculinizing treatment in trans men,whilst trans women are routinely treated with estradiol agents in combination with anti-androgens or gonadotrophinreleasing hormone agonists if testes are present.Exogenous androgenic steroids,estradiol agents,and anti-androgens have been implicated in a series of hepatotoxic effects.Thus,liver integrity is a major concern with the long-term administration of cross-sex therapy.Hepatic tissue is susceptible to coronavirus disease 19(COVID-19)through various pathophysiological mechanisms.Special consideration should be paid to minimize the risk of hepatic damage from the potential cumulative effect of COVID-19 and gender-affirming treatment in transgender patients.Appropriate care is significant,with continuous laboratory monitoring,clinical observation and,if needed,specific treatment,especially in severe cases of infection and in persons with additional liver pathologies.The pandemic can be an opportunity to provide equal access to care for all and increase the resilience of the transgender population.

关 键 词：Transgender persons Drug induced liver injury COVID-19 

分 类 号：R575[医药卫生—消化系统]